These results support the finding that it is necessary to administer the recombinant IL-12 and an IL-6 inhibitor well in advance of the start of anti-PD-1 immunotherapy so that there is sufficient time for the tumor micro-environment to be reconfigured into a manner which is more conducive to treatment response. This evidence concerns the gene IL6 and neoplasm.